Axel-Sven Malkomes
Director/Board Member at CELLECTIS S.A.
Net worth: - $ as of 2024-04-29
Axel-Sven Malkomes active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CELLECTIS S.A. | Director/Board Member | 2022-06-27 | - |
| Independent Dir/Board Member | 2022-06-27 | - | |
Medigene Immunotherapies GmbH
 Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Chief Executive Officer | - | - |
Career history of Axel-Sven Malkomes
Former positions of Axel-Sven Malkomes
| Companies | Position | Start | End |
|---|---|---|---|
| MEDIGENE AG | Director of Finance/CFO | 2019-03-31 | 2022-03-30 |
| BARCLAYS PLC | Director/Board Member | 2016-02-29 | 2019-02-28 |
| Corporate Officer/Principal | 2016-02-29 | 2019-02-28 | |
| SOCIÉTÉ GÉNÉRALE | Corporate Officer/Principal | 2009-12-31 | 2015-12-31 |
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
 3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland Gesellschaft für Industriebeteiligungen mbH (3i Deutschland) is the German private equity subsidiary of 3i Group Plc (LSE: III) in Great Britain. Established in Frankfurt in 1984, the firm invests in small and medium-sized German companies at all stages of development, from start-ups to established businesses. In addition to the Frankfurt office, 3i Deutschland has offices in Munich and Stuttgart. They drive their investment focus and decisions from their Frankfurt and Munich offices, and the team collaborates with Swiss colleagues in Zurich and 3i's network across Europe, Asia and the U.S. to invest in a wide range of industry sectors. | Private Equity Investor | - | 2009-12-31 |
| MERCK KGAA | Corporate Officer/Principal | - | - |
Statistics
International
| Germany | 5 |
| France | 3 |
| United Kingdom | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Private Equity Investor | 1 |
Sectoral
| Health Technology | 5 |
| Finance | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 5 |
|---|---|
| MEDIGENE AG | Health Technology |
| BARCLAYS PLC | Finance |
| SOCIÉTÉ GÉNÉRALE | Finance |
| MERCK KGAA | Health Technology |
| CELLECTIS S.A. | Health Technology |
| Private companies | 2 |
|---|---|
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland Gesellschaft für Industriebeteiligungen mbH (3i Deutschland) is the German private equity subsidiary of 3i Group Plc (LSE: III) in Great Britain. Established in Frankfurt in 1984, the firm invests in small and medium-sized German companies at all stages of development, from start-ups to established businesses. In addition to the Frankfurt office, 3i Deutschland has offices in Munich and Stuttgart. They drive their investment focus and decisions from their Frankfurt and Munich offices, and the team collaborates with Swiss colleagues in Zurich and 3i's network across Europe, Asia and the U.S. to invest in a wide range of industry sectors. | Finance |
Medigene Immunotherapies GmbH
Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Part of MediGene AG, Medigene Immunotherapies GmbH develops immunotherapy to treat cancer. The company is based in Planegg, Germany. The German company was founded in 2013 by Thomas Blankenstein, Dolores J. Schendel. The CEO is Axel-Sven Malkomes. Medigene Immunotherapies was acquired by MediGene AG on January 27, 2014 for $13.05 million. | Health Technology |
- Stock Market
- Insiders
- Axel-Sven Malkomes
- Experience
